Peptide News Digest

Ascendis Q2 €315M +105%, Kailera Ribupatide Phase 3 H1 2027, Samsung-PolyPeptide $1.8B Tender, Novo -6% Thursday

Ascendis Q2 €315M +105% YoY led by YORVIPATH €252M. Kailera ribupatide oral Phase 3 H1 2027. Samsung-PolyPeptide tender prospectus. Novo -6% on Lilly gap.

4 stories · Covering industry, clinical-trials

Editor's Note

Thursday's peptide news is dense with commercial-stage rare-disease franchise updates, obesity-pipeline pacing, and CDMO consolidation. Ascendis Pharma (NASDAQ: ASND) reported Q2 2026 product revenue of €315 million (+105% year-over-year) driven by YORVIPATH (palopegteriparatide, a TransCon parathyroid hormone peptide analog for chronic hypoparathyroidism) at €252 million, SKYTROFA (lonapegsomatropin, a TransCon growth hormone peptide) at €55 million, and YUVIWEL (TransCon CNP for achondroplasia) at €8 million with more than 220 US patient enrollments through July 31; the YUVIWEL launch directly competes with BioMarin's Voxzogo (vosoritide) in the same achondroplasia indication, opening a new front in the pediatric peptide-analog commercial category. Kailera Therapeutics (NASDAQ: KLRA) reported August 12 Q2 2026 results and disclosed an active Investigational New Drug (IND) application with the FDA for ribupatide oral (KAI-9531-T), with global Phase 3 obesity trials planned to initiate in H1 2027 following Hengrui Pharma's Phase 2 data showing up to 12.1% mean weight loss and 38.6% of participants achieving at least 15% weight loss at 25 mg and 50 mg doses. Samsung Biologics' all-cash tender offer to acquire PolyPeptide Group AG for CHF 44.31 per share (CHF 1.46 billion / $1.8 billion, 40% premium) continues to progress, with the formal tender offer prospectus expected to be published by end of August 2026 and shareholder acceptance from PolyPeptide's largest shareholder Draupnir Holding B.V. (55.65% stake) already committed; the deal is expected to close towards the end of 2026 and would substantially expand Samsung's peptide CDMO manufacturing footprint. And Novo Nordisk (NYSE: NVO) shares fell approximately 6% Thursday on broker downgrade citing continued franchise-gap pressure from Eli Lilly's tirzepatide franchise and the CagriSema head-to-head miss versus tirzepatide (23.0% versus 25.5% weight loss at 84 weeks in the REDEFINE 4 head-to-head Phase 3 trial).

Industry

Ascendis Pharma (NASDAQ: ASND) Reported Thursday August 13 Q2 2026 Financial Results With Product Revenue of €315 Million (+105% Year-Over-Year), Anchored by YORVIPATH (Palopegteriparatide, a TransCon Parathyroid Hormone Peptide Analog for Chronic Hypoparathyroidism) at €252 Million on Consistent New Patient Demand in the US and Continued Ex-US Global Launch Expansion With Full Reimbursement, SKYTROFA (Lonapegsomatropin, a TransCon Growth Hormone Peptide) at €55 Million, and YUVIWEL (TransCon C-Type Natriuretic Peptide for Achondroplasia) at €8 Million With More Than 220 US Patient Enrollments Through July 31, 2026; The YUVIWEL Launch Positions Ascendis Directly Against BioMarin's Voxzogo (Vosoritide) in the Same Achondroplasia Pediatric Indication and Opens a New Front in the CNP Peptide Analog Commercial Category

Ascendis Pharma (NASDAQ: ASND) reported Thursday August 13, 2026 Q2 2026 financial results with product revenue of €315 million (+105% year-over-year). YORVIPATH (palopegteriparatide, a TransCon parathyroid hormone peptide analog for chronic hypoparathyroidism) delivered €252 million on consistent new patient demand in the US and continued ex-US global launch expansion with full reimbursement in additional markets. SKYTROFA (lonapegsomatropin, a TransCon growth hormone peptide for pediatric growth hormone deficiency) delivered €55 million. YUVIWEL (TransCon C-type natriuretic peptide for achondroplasia) delivered €8 million with more than 220 US patient enrollments through July 31, 2026. Total Q2 revenue reached €339 million (+100% YoY) including €24 million in collaboration and milestone income. The YUVIWEL launch positions Ascendis directly against BioMarin's Voxzogo (vosoritide) in the same achondroplasia pediatric indication, opening a new front in the CNP peptide analog commercial category. YORVIPATH's €252 million quarterly revenue trajectory suggests a $1+ billion annual run-rate for the peptide franchise by end of 2026, a notable rare-disease peptide launch magnitude. Ascendis's TransCon platform uses a transient linker chemistry to release parent drug over an extended half-life, allowing weekly dosing of peptides that natively have short in vivo lifespans.

#ascendis-pharma #asnd #yorvipath #palopegteriparatide #skytrofa #lonapegsomatropin #yuviwel #transcon-cnp #chronic-hypoparathyroidism #achondroplasia #biomarin #voxzogo #q2-2026-earnings #transcon-platform
Clinical Trials

Kailera Therapeutics (NASDAQ: KLRA) Reported August 12 Q2 2026 Financial Results and Disclosed an Active Investigational New Drug (IND) Application With the US FDA for Ribupatide Oral (KAI-9531-T), a Triple Agonist (GLP-1/GIP/Glucagon) Peptide for Obesity Being Co-Developed With Hengrui Pharma, With Global Phase 3 Obesity Trials Planned to Initiate in H1 2027 Following Hengrui's Phase 2 Trial in Adults With Obesity That Documented Up to 12.1% Mean Weight Loss With No Observed Plateau at Week 26 and Up to 38.6% of Participants Achieving at Least 15% Weight Loss at the 25 mg and 50 mg Once-Daily Oral Doses; A Ribupatide Injection Phase 2b High-Dose Trial in Obesity Is Fully Enrolled With Data Anticipated in Mid-2027

Kailera Therapeutics (NASDAQ: KLRA) reported August 12, 2026 Q2 2026 financial results and disclosed an active Investigational New Drug (IND) application with the US FDA for ribupatide oral (KAI-9531-T), a triple agonist (GLP-1, GIP, and glucagon receptor) peptide for obesity being co-developed with Hengrui Pharma. Global Phase 3 obesity trials are planned to initiate in H1 2027. Phase 2 data foundation: Hengrui's Phase 2 trial in adults with obesity documented up to 12.1% mean weight loss with no observed plateau at Week 26 and up to 38.6% of participants achieving at least 15% weight loss at the 25 mg and 50 mg once-daily oral doses. A ribupatide injection Phase 2b high-dose trial in obesity is fully enrolled with data anticipated in mid-2027. Ribupatide competes mechanistically with Eli Lilly's retatrutide (once-weekly injectable triple agonist, roughly 28.7% weight loss at 68 weeks in Phase 3 TRIUMPH-4) in the triple-agonist class. The oral formulation could compete with Lilly's orforglipron (oral small-molecule GLP-1 agonist, roughly 7.5-11.2% weight loss over 72 weeks) and Novo Nordisk's Wegovy pill (oral semaglutide 25/50 mg). Kailera holds US and ex-China commercial rights via a license from Hengrui.

#kailera-therapeutics #klra #ribupatide #kai-9531 #hengrui-pharma #triple-agonist #glp-1-gip-glucagon #oral-obesity-drug #ind-application #phase-2 #phase-3-h1-2027 #retatrutide #orforglipron
Industry

Samsung Biologics' All-Cash Tender Offer to Acquire PolyPeptide Group AG for CHF 44.31 per Share (CHF 1.46 Billion / $1.8 Billion, Representing a 40% Premium to the Undisturbed Share Price) Continues to Progress With the Formal Tender Offer Prospectus Expected to Be Published by End of August 2026 and Shareholder Acceptance From PolyPeptide's Largest Individual Shareholder Draupnir Holding B.V. (Approximately 55.65% Stake) Already Committed to Tender; The Transaction Would Substantially Expand Samsung Biologics' Peptide CDMO Manufacturing Footprint Beyond Its Existing Antibody and Antibody-Drug Conjugate Focus and Position the Combined Entity to Address the Rapidly Growing Peptide Therapeutics Demand Particularly in Obesity and Diabetes (GLP-1 Therapies); Closing Expected Towards the End of 2026 Subject to Minimum Acceptance Threshold of 66⅔% and Applicable Regulatory Approvals

Samsung Biologics' all-cash tender offer to acquire PolyPeptide Group AG for CHF 44.31 per share (CHF 1.46 billion / $1.8 billion, representing a 40% premium to the undisturbed share price of CHF 31.65) continues to progress. The formal tender offer prospectus is expected to be published by end of August 2026 and will remain open for a minimum of twenty trading days on the SIX Swiss Exchange following a ten trading-day cooling-off period under Swiss takeover law. PolyPeptide's largest individual shareholder Draupnir Holding B.V. (owning approximately 55.65% of shares outstanding) has committed to tender all of its shares into the offer. PolyPeptide's independent Board of Directors unanimously recommends that shareholders accept Samsung Biologics' offer. The transaction would substantially expand Samsung Biologics' peptide CDMO manufacturing footprint beyond its existing antibody and antibody-drug conjugate focus, positioning the combined entity to address the rapidly growing peptide therapeutics demand particularly in obesity and diabetes GLP-1 therapies (Novo Nordisk Wegovy and Ozempic, Eli Lilly Zepbound and Mounjaro), amylin analogs (cagrilintide), and next-generation combination peptide drugs. PolyPeptide operates commercial-scale peptide API manufacturing across the US, Europe, and India. Closing is expected towards the end of 2026 subject to a minimum acceptance threshold of 66⅔% and applicable regulatory approvals.

#samsung-biologics #polypeptide-group #tender-offer #1-8-billion-acquisition #peptide-cdmo #peptide-manufacturing #chf-44-31 #draupnir-holding #40-percent-premium #multi-modality-cdmo #acquisition
Industry

Novo Nordisk (NYSE: NVO) Shares Fell Approximately 6% Thursday August 13, 2026 on Broker Downgrade Citing Continued Franchise-Gap Pressure From Eli Lilly's (NYSE: LLY) Tirzepatide Franchise and the CagriSema Head-to-Head Miss Against Tirzepatide (23.0% Versus 25.5% Weight Loss at 84 Weeks in the REDEFINE 4 Head-to-Head Phase 3 Trial); The August 4 H1 2026 Earnings Release Raised Full-Year 2026 Sales Guidance to Down 3% From Prior Down 8% Midpoint but the Broader Investor Narrative Continues to Focus on Novo's Ability to Defend GLP-1 Franchise Economics Against Eli Lilly's Q2 2026 $23 Billion Revenue Blowout (+48% YoY), Foundayo (Orforglipron) $98 Million First Commercial Quarter, and Retatrutide's 28.7% Phase 3 TRIUMPH-4 Weight Loss Result

Novo Nordisk (NYSE: NVO) shares fell approximately 6% Thursday August 13, 2026 on broker downgrade citing continued franchise-gap pressure from Eli Lilly's tirzepatide franchise (Mounjaro + Zepbound) and the CagriSema head-to-head miss against tirzepatide. Specifics: CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg fixed-dose combination) reached 23.0% weight loss at 84 weeks versus tirzepatide 15 mg's 25.5% in the REDEFINE 4 head-to-head Phase 3 trial published in early August 2026. The August 4 H1 2026 earnings release raised full-year 2026 sales guidance to down 3% from a prior down 8% midpoint at constant exchange rates. The broader investor narrative continues to focus on Novo's ability to defend GLP-1 franchise economics against Eli Lilly's Q2 2026 $23 billion revenue blowout (+48% year-over-year), Foundayo (orforglipron) $98 million first commercial quarter, and retatrutide's 28.7% Phase 3 TRIUMPH-4 weight loss result at 68 weeks. Analyst attention now shifts to Novo's Wegovy 7.2 mg higher-dose FDA review, the amycretin oral amylin monotherapy Phase 1b program (roughly 22% weight loss at Week 36), and next-generation candidates in Novo's pipeline. Investors are also watching the CagriSema FDA decision expected late 2026 and whether the label expansion strategy can offset the competitive pressure.

#novo-nordisk #nvo #eli-lilly #lly #broker-downgrade #franchise-gap #cagrisema #redefine-4 #tirzepatide #foundayo #retatrutide #wegovy-7-2-mg #amycretin #6-percent-decline